Shield Therapeutics (LON:STX) Share Price Passes Below Fifty Day Moving Average – Here’s Why

Shield Therapeutics plc (LON:STX) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 10.65 and traded as low as GBX 10. Shield Therapeutics shares last traded at GBX 10.60, with a volume of 1,701,659 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Peel Hunt restated a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a research report on Friday, November 7th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Shield Therapeutics presently has an average rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Trading Up 1.0%

The stock has a market cap of £113.21 million, a PE ratio of -5.30 and a beta of 1.42. The company’s 50-day moving average price is GBX 10.65 and its 200 day moving average price is GBX 8.45. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.